Notch3 is involved in the proliferation of renal cancer cells via regulation of cell cycle progression and HIF‑2&alpha;

Han,Qipeng; Han,Fangzhu; Fan,Yisheng; Lian,Bowen; Xiao,Jinyang; Sun,Wei; Han,Dongbing; Kou,Hongbo; Li,Chunyan; Wu,Bin

doi:10.3892/ol.2020.12242

December-2020 Volume 20 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December-2020 Volume 20 Issue 6

Full Size Image

Article

Notch3 is involved in the proliferation of renal cancer cells via regulation of cell cycle progression and HIF‑2α

Authors:
- Qipeng Han
- Fangzhu Han
- Yisheng Fan
- Bowen Lian
- Jinyang Xiao
- Wei Sun
- Dongbing Han
- Hongbo Kou
- Chunyan Li
- Bin Wu
View Affiliations / Copyright

Affiliations: Department of Urinary Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Center of Science Experiments, China Medical University, Shenyang, Liaoning 110122, P.R. China, Department of Urinary Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning 110001, P.R. China
Article Number: 379
|
Published online on: October 22, 2020

https://doi.org/10.3892/ol.2020.12242
Expand metrics +

Abstract

Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system. Although deregulation of the Notch signaling pathway is common in RCC and is involved in the tumorigenic process, the exact role of Notch3 and its underlying molecular mechanism in RCC, particularly in hypoxia, remain unknown. In the present study, RO4929097, a Notch3 inhibitor, was used to alter NICD3 expression. A Cell Counting Kit‑8 assay, EdU incorporation assay, colony formation assay, flow cytometry and western blot analysis were used to investigate the effects of altered NICD3 expression on cell proliferation, cell cycle progression and HIF‑2α protein expression. The results of western blot analysis showed that RO4929097 dose‑dependently decreased the expression of Notch3 intracellular domain (NICD3) in 786‑O and ACHN cells, which originate from clear cell RCC (ccRCC). The results of the Cell Counting Kit‑8, EdU incorporation and colony formation assays demonstrated that downregulation of NICD3 significantly suppressed cell proliferation in both normoxia and hypoxia. In addition, flow cytometry and western blot analysis demonstrated that hypoxia (2% O₂) promoted cell cycle progression in ccRCC cells with the increased expression of G₁‑S transition‑associated proteins, namely cyclin‑dependent kinase (CDK)4 and cyclin D1, while downregulation of NICD3 exerted negative effects on cell cycle progression, and the expression levels of CDK4 and cyclin D1. Furthermore, western blot analysis revealed that 2% O₂‑induced upregulated hypoxia‑inducible factor‑2α (HIF‑2α) expression decreased following downregulation of NICD3 in 786‑O and ACHN cells. Following transfection of the vector containing the NICD3 coding sequence, HIF‑2α, CDK4, cyclin D1 and proliferating cell nuclear antigen expression,that were inhibited by RO4929097 in hypoxia, were rescued. Collectively, the results of the present study suggest that Notch3 is closely associated with the cell proliferation of ccRCC cells by regulating the cell cycle and HIF‑2α.

View Figures

View References

1	Bergerot P, Lamb P, Wang E and Pal SK: Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: Rationale and clinical evidence. Mol Cancer Ther. 18:2185–2193. 2019. View Article : Google Scholar : PubMed/NCBI
2	Baba M, Hirai S, Yamada-Okabe H, Hamada K, Tabuchi H, Kobayashi K, Kondo K, Yoshida M, Yamashita A, Kishida T, et al: Loss of von hippel-lindau protein causes cell density dependent deregulation of cyclinD1 expression through hypoxia-inducible factor. Oncogene. 22:2728–2738. 2003. View Article : Google Scholar : PubMed/NCBI
3	Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG and Krohn KA: Hypoxia and glucose metabolism in malignant tumors: Evaluation by [¹⁸F]fluoromisonidazole and [¹⁸F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 10:2245–2252. 2004. View Article : Google Scholar : PubMed/NCBI
4	Schödel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P and Mole DR: Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol. 69:646–657. 2016. View Article : Google Scholar : PubMed/NCBI
5	Artavanis-Tsakonas S, Matsuno K and Fortini ME: Notch signaling. Science. 268:225–232. 1995. View Article : Google Scholar : PubMed/NCBI
6	Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: Cell fate control and signal integration in development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
7	Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, Li W, Shenoy N, Giricz O, Choudhary G, et al: Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer. J Biol Chem. 292:837–846. 2017. View Article : Google Scholar : PubMed/NCBI
8	Jędroszka D, Orzechowska M and Bednarek AK: Predictive values of notch signalling in renal carcinoma. Arch Med Sci. 13:1249–1254. 2017. View Article : Google Scholar : PubMed/NCBI
9	Fendler A, Bauer D, Busch J, Jung K, Wulf-Goldenberg A, Kunz S, Song K, Myszczyszyn A, Elezkurtaj S, Erguen B, et al: Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. Nat Commun. 11:9292020. View Article : Google Scholar : PubMed/NCBI
10	Hosseini-Alghaderi S and Baron M: Notch3 in development, health and disease. Biomolecules. 10:4852020. View Article : Google Scholar
11	Olsauskas-Kuprys R, Zlobin A and Osipo C: Gamma secretase inhibitors of notch signaling. Onco Targets Ther. 6:943–955. 2013.PubMed/NCBI
12	Sonnenschein C and Soto AM: Symposium on the control of cell proliferation and cancer. Cancer Res. 49:61611989.PubMed/NCBI
13	Hubbi ME and Semenza GL: Regulation of cell proliferation by hypoxia-inducible factors. Am J Physiol Cell Physiol. 309:C775–C782. 2015. View Article : Google Scholar : PubMed/NCBI
14	Katz D, Ito E, Lau KS, Mocanu JD, Bastianutto C, Schimmer AD and Liu FF: Increased efficiency for performing colony formation assays in 96-well plates: Novel applications to combination therapies and high-throughput screening. Biotechniques. 44:ix–xiv. 2008. View Article : Google Scholar : PubMed/NCBI
15	Braselmann H, Michna A, Heß J and Unger K: CFAssay: Statistical analysis of the colony formation assay. Radiat Oncol. 10:2232015. View Article : Google Scholar : PubMed/NCBI
16	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
17	Raju RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL and Ratcliffe PJ: Contrasting properties of hypoxia-inducible Factor 1 (HIF-1) and HIF-2 in von hippel-lindau-associated renal cell carcinoma. Mol Cell Biol. 25:5675–5686. 2005. View Article : Google Scholar : PubMed/NCBI
18	Joshi I, Minter LM, Telfer J, Demarest RM, Capobianco AJ, Aster JC, Sicinski P, Fauq A, Golde TE and Osborne BA: Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood. 113:1689–1698. 2009. View Article : Google Scholar : PubMed/NCBI
19	Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL and Dang CV: Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem. 276:7919–7926. 2001. View Article : Google Scholar : PubMed/NCBI
20	Green SL, Freiberg RA and Giaccia AJ: P21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol Cell Biol. 21:1196–1206. 2001. View Article : Google Scholar : PubMed/NCBI
21	Chen J, Imanaka N, Chen J and Griffin JD: Hypoxia potentiates notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer. 102:351–360. 2010. View Article : Google Scholar : PubMed/NCBI
22	Michalides R: Prognosis for G1 cell-cycle regulators: Useful for predicting course of disease and for assessment of therapy in cancer. J Pathol. 188:341–343. 1999. View Article : Google Scholar : PubMed/NCBI
23	Milde-Langosch K and Riethdorf S: Role of cell-cycle regulatory proteins in gynecological cancer. J Cell Physiol. 196:224–244. 2003. View Article : Google Scholar : PubMed/NCBI
24	He L, Lu N, Dai Q, Zhao Y, Zhao L, Wang H, Li Z, You Q and Guo Q: Wogonin induced G1 cell cycle arrest by regulating wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology. 312:36–47. 2013. View Article : Google Scholar : PubMed/NCBI
25	Wang J, Li Q, Yuan J, Wang J, Chen Z, Liu Z, Li Z, Lai Y, Gao J and Shen L: CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. J Transl Med. 15:1272017. View Article : Google Scholar : PubMed/NCBI
26	Salama R, Masson N, Simpson P, Sciesielski LK, Sun M, Tian YM, Ratcliffe PJ and Mole DR: Heterogeneous effects of direct hypoxia pathway activation in kidney cancer. PLoS One. 10:e01346452015. View Article : Google Scholar : PubMed/NCBI
27	Shen C and Kaelin WG Jr: The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 23:18–25. 2013. View Article : Google Scholar : PubMed/NCBI
28	Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N and Murai M: Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α. Carcinogenesis. 28:529–536. 2007. View Article : Google Scholar : PubMed/NCBI
29	De Francesco EM, Maggiolini M and Musti AM: Crosstalk between notch, HIF-1α and GPER in breast cancer EMT. Int J Mol Sci. 19:20112018. View Article : Google Scholar
30	Marignol L, Rivera-Figueroa K, Lynch T and Hollywood D: Hypoxia, notch signalling, and prostate cancer. Nat Rev Urol. 10:405–413. 2013. View Article : Google Scholar : PubMed/NCBI
31	Kandasamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GS, Venugopal AK, Telikicherla D, Navarro JD, Mathivanan S, Pecquet C, et al: NetPath: A public resource of curated signal transduction pathways. Genome Biol. 11:R32010. View Article : Google Scholar : PubMed/NCBI
32	Yuan Y, Hilliard G, Ferguson T and Millhorn DE: Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von hippel-lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem. 278:15911–15916. 2003. View Article : Google Scholar : PubMed/NCBI
33	Mutvei AP, Landor SK, Fox R, Braune EB, Tsoi YL, Phoon YP, Sahlgren C, Hartman J, Bergh J, Jin S, et al: Notch signaling promotes a HIF2α-driven hypoxic response in multiple tumor cell types. Oncogene. 37:6083–6095. 2018. View Article : Google Scholar : PubMed/NCBI
34	Zimmer M, Ebert BL, Neil C, Brenner K, Papaioannou I, Melas A, Tolliday N, Lamb J, Pantopoulos K, Golub T and Iliopoulos O: Small molecule inhibitors of HIF-2a translation link its 5′-UTR iron-responsive element (IRE) to oxygen sensing. Mol Cell. 32:838–848. 2008. View Article : Google Scholar : PubMed/NCBI
35	Kong LY, Xi Z, Ma WT, Yang FY, Niu LD and Shi JH: Effects of notch signal on the expressions of HIF-α and autophagy-related genes BECLIN1, LC3I, LC3II in oxygen-glucose deprivation induced myocardial cell injury. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 35:165–168. 2019.(In Chinese). PubMed/NCBI
36	Yu N, Wu JL, Xiao J, Fan L, Chen SH and Li W: HIF-1α regulates angiogenesis via notch1/STAT3/ETBR pathway in trophoblastic cells. Cell Cycle. 18:3502–3512. 2019. View Article : Google Scholar : PubMed/NCBI
37	Moriyama H, Moriyama M, Ozawa T, Tsuruta D, Iguchi T, Tamada S, Nakatani T, Nakagawa K and Hayakawa T: Notch signaling enhances stemness by regulating metabolic pathways through modifying p53, NF-κB, and HIF-1α. Stem Cells Dev. 27:935–947. 2018. View Article : Google Scholar : PubMed/NCBI
38	Dang TP: Notch, apoptosis and cancer. Adv Exp Med Biol. 727:199–209. 2012. View Article : Google Scholar : PubMed/NCBI
39	Lu Z, Ren Y, Zhang M, Fan T, Wang Y, Zhao Q, Liu HM, Zhao W and Hou G: FLI-06 suppresses proliferation, induces apoptosis and cell cycle arrest by targeting LSD1 and Notch pathway in esophageal squamous cell carcinoma cells. Biomed Pharmacother. 107:1370–1376. 2018. View Article : Google Scholar : PubMed/NCBI